Treats obsessive compulsive disorder (OCD). ANDA 220328, held by Appco. Fluvoxamine Maleate.
As of Nov 16, 2026, ANDA 220328 (Fluvoxamine Maleate), held by Appco, was first approved by FDA on Apr 30, 2026, with 0 approved supplements and 0 published complete response letters.
Fluvoxamine maleate extended-release capsules are a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of obsessive compulsive disorder (OCD). Efficacy was demonstrated in: One 12-week study with fluvoxamine maleate extended-release capsules in adults. Two 10-week studies with immediate-release (IR) fluvoxamine tablets in adults and one 10-week study with IR fluvoxamine tablets in children and adolescents ( 14.1, 14.3 ). One maintenance study with IR fluvoxamine tablets. 1.1 Obsessive Compulsive Disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 30, 2026 | Original application | Approved | None posted |
| Fluvoxamine Maleate100MG · capsule, extended release;oral | Fluvoxamine Maleate | Rx |
| Fluvoxamine Maleate150MG · capsule, extended release;oral | Fluvoxamine Maleate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters